FDA advisory group to review peptide injections
A little-known advisory group to the US Food and Drug Administration (FDA) will meet this week to consider easing restrictions on certain peptides. These injectable substances are favored by wellness influencers and some medical professionals, who claim they enhance muscle recovery, alleviate inflammation, promote longevity, or improve overall health, reports BritPanorama.
The upcoming meeting provides insight into how drug regulators will respond to the growing popularity of peptides that remain unapproved by the FDA. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on Thursday and Friday to evaluate several controversial peptide treatments and discuss the potential for compounding pharmacies to dispense these substances.
In this meeting, the committee will assess seven peptides nominated for inclusion on the FDA’s 503A Bulks List, a registry of ingredients that compounding pharmacists are permitted to use for customized medications under specific legal conditions. Previous FDA panels have been predominantly made up of academics and researchers. However, the current committee under the second Trump administration consists largely of health professionals engaged in prescribing, producing, or promoting peptides.
Health and Human Services Secretary Robert F. Kennedy Jr. has voiced support for peptides, sharing his personal use of them and expressing a desire to relax existing restrictions. However, he faces resistance within the FDA, which has previously ruled that some peptides lack adequate safety data.
This meeting is crucial for determining whether certain peptides will transition closer to mainstream medical practice or remain largely outside of it. The FDA’s experts have indicated that there is insufficient evidence regarding the effectiveness and safety of these peptides to warrant their addition to the 503A Bulks List, suggesting they will recommend against this inclusion.
What are peptides?
Peptides are short chains of amino acids, essential for protein synthesis, and can be significant in medicine. Insulin, for instance, is a well-known peptide, as are popular GLP-1 medications for diabetes and obesity, like Ozempic and Wegovy. However, many of the peptides under review currently are not FDA-approved.
While some experts have expressed concerns regarding the safety of these experimental peptides, including risks of life-threatening allergic reactions, others argue that allowing FDA-regulated pharmacies to produce these medications might offer a safer alternative to purchasing unregulated products online.
Nonetheless, the ongoing debate is marked by tension, as critics worry that introducing these compounds in legitimate pharmacies could mislead patients into thinking they are proven safe and effective despite limited clinical trial data.
Which peptides are under review?
The peptides currently under consideration include:
- BPC-157 for ulcerative colitis
- KPV for wound healing and inflammatory conditions
- TB-500 for wound healing
- MOTs-C for obesity and osteoporosis
- Emideltide for opioid withdrawal, chronic insomnia, and narcolepsy
- Semax for certain neurological disorders
- Epitalon for insomnia
The committee will determine whether to allow access to these peptides through state-licensed compounding pharmacies, with potential implications for their mainstream acceptance in medical practice.
The outcome of this meeting could reshape access to peptide therapies in the US, altering how patients receive them amidst an evolving landscape of wellness and medical regulation. The complexity of ensuring safety and efficacy remains at the forefront of these discussions, illustrating the continuing challenges of navigating modern medicine’s intersection with wellness culture.
